Logo image of PRME

PRIME MEDICINE INC (PRME) Stock Fundamental Analysis

NASDAQ:PRME - Nasdaq - US74168J1016 - Common Stock - Currency: USD

4.09  -0.12 (-2.85%)

After market: 4.0817 -0.01 (-0.2%)

Fundamental Rating

3

Overall PRME gets a fundamental rating of 3 out of 10. We evaluated PRME against 553 industry peers in the Biotechnology industry. The financial health of PRME is average, but there are quite some concerns on its profitability. PRME is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRME had negative earnings in the past year.
PRME had a negative operating cash flow in the past year.
In the past 5 years PRME always reported negative net income.
PRME had a negative operating cash flow in each of the past 5 years.
PRME Yearly Net Income VS EBIT VS OCF VS FCFPRME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of PRME (-61.56%) is comparable to the rest of the industry.
PRME has a worse Return On Equity (-188.93%) than 66.55% of its industry peers.
Industry RankSector Rank
ROA -61.56%
ROE -188.93%
ROIC N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
PRME Yearly ROA, ROE, ROICPRME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PRME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRME Yearly Profit, Operating, Gross MarginsPRME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

PRME does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRME has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRME has been increased compared to 5 years ago.
There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRME Yearly Shares OutstandingPRME Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PRME Yearly Total Debt VS Total AssetsPRME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.21, we must say that PRME is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.21, PRME is in line with its industry, outperforming 47.92% of the companies in the same industry.
There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.21
ROIC/WACCN/A
WACC9.82%
PRME Yearly LT Debt VS Equity VS FCFPRME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

PRME has a Current Ratio of 4.78. This indicates that PRME is financially healthy and has no problem in meeting its short term obligations.
PRME has a Current ratio (4.78) which is in line with its industry peers.
A Quick Ratio of 4.78 indicates that PRME has no problem at all paying its short term obligations.
PRME has a Quick ratio (4.78) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.78
Quick Ratio 4.78
PRME Yearly Current Assets VS Current LiabilitesPRME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.15% over the past year.
Looking at the last year, PRME shows a very strong growth in Revenue. The Revenue has grown by 550.76%.
EPS 1Y (TTM)26.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)550.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%146.02%

3.2 Future

Based on estimates for the next years, PRME will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.59% on average per year.
Based on estimates for the next years, PRME will show a very strong growth in Revenue. The Revenue will grow by 99.72% on average per year.
EPS Next Y19.87%
EPS Next 2Y17.23%
EPS Next 3Y12.5%
EPS Next 5Y8.59%
Revenue Next Year542.52%
Revenue Next 2Y265.79%
Revenue Next 3Y218.22%
Revenue Next 5Y99.72%

3.3 Evolution

PRME Yearly Revenue VS EstimatesPRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2029 2030 2031 2032 200M 400M 600M
PRME Yearly EPS VS EstimatesPRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRME Price Earnings VS Forward Price EarningsPRME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRME Per share dataPRME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PRME's earnings are expected to grow with 12.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.23%
EPS Next 3Y12.5%

More info and screens

0

5. Dividend

5.1 Amount

PRME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRIME MEDICINE INC

NASDAQ:PRME (7/28/2025, 6:02:27 PM)

After market: 4.0817 -0.01 (-0.2%)

4.09

-0.12 (-2.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners56.55%
Inst Owner Change0.04%
Ins Owners16.29%
Ins Owner Change1.37%
Market Cap550.11M
Analysts81.11
Price Target7.5 (83.37%)
Short Float %20.27%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-22.51%
Max EPS beat(2)22.47%
EPS beat(4)1
Avg EPS beat(4)-5.26%
Min EPS beat(4)-22.51%
Max EPS beat(4)22.47%
EPS beat(8)2
Avg EPS beat(8)-9.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)340.15%
Min Revenue beat(2)35.89%
Max Revenue beat(2)644.42%
Revenue beat(4)2
Avg Revenue beat(4)120.73%
Min Revenue beat(4)-100%
Max Revenue beat(4)644.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-47.03%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)-11.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.36%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)31.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)30.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 143.03
P/FCF N/A
P/OCF N/A
P/B 5.14
P/tB 5.14
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.03
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.56%
ROE -188.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.5%
Cap/Sales 192.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.78
Quick Ratio 4.78
Altman-Z -3.21
F-Score5
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)343.92%
Cap/Depr(5y)671.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y19.87%
EPS Next 2Y17.23%
EPS Next 3Y12.5%
EPS Next 5Y8.59%
Revenue 1Y (TTM)550.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%146.02%
Revenue Next Year542.52%
Revenue Next 2Y265.79%
Revenue Next 3Y218.22%
Revenue Next 5Y99.72%
EBIT growth 1Y3.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.36%
EBIT Next 3Y7.42%
EBIT Next 5YN/A
FCF growth 1Y19.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.16%
OCF growth 3YN/A
OCF growth 5YN/A